🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Ben Creelan, MD Moffitt Cancer Center : Interesting Phase 1 trial shows durable CRs to adoptive cell transfer using TILs in #NSCLC. Many patients were low/no PDL1 and had oncogene drivers. Looking forward to seeing future work in this area. #AACR20 #lcsm #lungcancer EGFR Resisters

Genome and immunology as a married couple. Association between genomic alterations and PD-L1 expression #AACR2020

Another new Review, live online. In this one, Alexander Drilon MD and co-authors discuss the topic of 'MET-dependent solid tumours — molecular diagnosis and targeted therapy' nature.com/articles/s4157… #caxtx

🥁🥁🥁By popular demand now the full list of US FDA approvals for #lungcancer from May 2020. 7 approvals ( YES!!! SEVEN) in May alone and now one for RET + NSCLC on September 4th 2020. Its a win for all patients with lung cancer. 👏👏👏 OncoAlert #oncoalert

#ESMO20, even if I deeply miss the human experience & interaction with friends & colleagues, this publication from CDC on SARS-Cov2 transmission during an international flight reminds us on why we do this virtually wwwnc.cdc.gov/eid/article/26…

.ASCO's Association for Clinical Oncology and American Cancer Society urge CDC to "review the emerging evidence about the impact of #COVID19 on people with cancer and to place these patients in the appropriate tier of allocation based on their risk." cancerletter.com/articles/20210…

Vaccination #COVID19 : Plaidoyer des Groupes Coopérateurs en Oncologie pour une priorisation des patients atteints de cancers évolutifs, sans limite d’âge gco-cancer.org/images/Plaidoy… IFCT lung Fédération Francophone de Cancérologie Digestive Lysa Lymphoma Intergroupe ORL Arcagy-Gineco La Ligue contre le cancer #VaccininfoCOVID

#Vaccin & personnes atteintes de cancer : 1. La Ligue demande que les personnes malades du cancer, en cours de traitement, immunodéprimées, fragilisées et menacées de développer des formes graves de la #Covid_19, soient incluses dans les priorités de la campagne de #vaccination.

A lire aujourd'hui dans Le Figaro ↪Recommandations pour un dépistage du cancer du poumon Société de Pneumologie de Langue Française (SPLF) IFCT lung #SIT ↪Résultats 1er et 2ème tour de dépistage dans Département de la Somme @Abbeville_Somme Prigent Anne lefigaro.fr/sciences/cance…

Here's a "toll-free" link for free access to both of these viewpoints, good for 1 month: by me and Bishal Gyawali, MD, PhD, FASCO: jamanetwork.com/journals/jamao… by Nathan A. Pennell MD, PhD, FASCO: jamanetwork.com/journals/jamao… Thanks to JAMA Oncology for access! #LCSM #ADAURA

En direct de la #JIFCT2021 avec un focus sur les études et groupes de travail IFCT couvrant un panorama de + en + large des situations cliniques rencontrées en oncologie thoracique (BRAF, KRAS, Stade III, Péri-opératoire, stade IV...). Mon Réseau Cancer du Poumon @INCa_veillePro IFCT lung

Proud to lead tonight the new IFCT lung scientific committee. Welcome to new members : Aurélie Swalduz Toffart Anne-Claire chantal decroisette Bennouna Jaafar Dr CAV🫁🩻🏥 Celine Mascaux cadranel jacques and Pascale Tomasini. Awesome team committed to clinical research in thoracic oncology 😄.

Présentation du réseau structurant « Lésions prenéoplasiques » du Cancéropôle Est par ses animateurs Celine Mascaux et @lab_metzger #12ForumDijon

C'est parti pour les #JAD22 à CHRU Strasbourg ! Au programme : une revue des grandes publications de l'année, des partages d'expériences pour le suivi des patients à domicile, la prise en charge des métastases osseuses #NSCLC #LCSM Celine Mascaux Quoix Elisabeth denis Moro-Sibilot Nicolas Girard

For readers interested in bispecific antibodies for cancer therapy, here's a comprehensive recent review bit.ly/3T7gZkH rdcu.be/dIULN

Remarque pertinente #invivox

Interested in cell therapies in oncology? A new landscape analysis from Cancer Research Institute Institute and IQVIA discusses clinical research and real-world data on the use and implementation of this modality bit.ly/4e2BlF8

#ASCO24 Dr. Ben Solomon presents the 5y update from CROWN: randomized phase III study of 1L lorlatinib vs crizotinib for advanced #ALK NSCLC (n=296). At 5y, median PFS still has not been reached!

Early Life Exposures and the Development of COPD across the Life Course. atsjournals.org/doi/10.1164/rc… ATS Blue Journal